Acellular pertussis vaccine based on outer membrane vesicles capable of conferring both long-lasting immunity and protection against different strain genotypes

GAILLARD ME; BOTTERO D; ERREA A; ORMAZABAL MAXIMILIANO; ZURITA ME; MORENO G; RUMBO M,; CASTUMA C; BARTEL E; FLORES D; PETER VAN DER LEY; ARNO VAN DER ARK; HOZBOR D

VACCINE

ELSEVIER SCI LTD

Lugar: Amsterdam; Año: 2013 p. 1231 - 1238

0264-410X

Despite high vaccination coverage rates, pertussis continues to be a global concern, with increased inci-dence widely noted. The current pertussis epidemiologic situation has been mainly attributed to waningimmunity and pathogen adaptation. To improve the disease control, a new generation of vaccines capableto overcome those weaknesses associated to the current vaccines need to be developed. Previously wehave demonstrated that the outer membrane vesicles obtained from the recombinant Bordetella pertussisstrain expressing PagL enzyme (OMVsBpPagL) are good vaccine candidates to protect against pertussis.In this work the OMVsBpPagLformulated with diphtheria and tetanus toxoids (TdapOMVsBpPagL) was usedto evaluate its capacity to offer protection against Argentinean clinical isolates and to induce long-termimmunity. To these aims BALB/c mice were immunized with TdapOMVsBpPagLand challenged with sub-lethal doses of the clinical isolate Bp106 selected as a representative circulating isolate. Comparisonswith a current commercial Tdap vaccine used at a dose in which pertussis toxin level was equivalentto that of TdapOMVsBpPagLwere performed. With the normalized doses of both vaccines we observed thatTdapOMVsBpPagLprotected against the clinical isolate infection, whereas current commercial Tdap vaccineshowed little protection against such pathogen. Regarding long-term immunity we observed that theTdapOMVsBpPagLprotective capacity against the recommended WHO reference strain persisted at least 9months. In agreement with these results TdapOMVsBpPagLinduced Th1 and Th2 immune response. In con-trast, commercial Tdap induced Th2 but weak Th1 responses. All results presented here showed thatTdapOMVsBpPagLis an interesting formulation to be considered for the development of novel acellularmulti-antigen vaccine.